Endpoints News
WuXi Biologics' new timeline for its Massachusetts factory Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
22 June, 2026
THE AVID EFFECT IS EXECUTION WITH PRECISION & PREDICTABILITY
Your Program. Delivered with Confidence.
sponsored by Avid Bioservices, Inc.
presented by HKSTP
The Next Decade of Biotech: Con­nect­ing the World via Cross-Bor­der Or­ches­tra­tors
spotlight
top stories
1. HHS rolls out sweeping clinical trial reforms to counter China, RFK Jr. says
2. After 'redesign,' WuXi Biologics sets new timeline for Massachusetts factory completion
3. Post-Hoc Live: Are the China hawks winning?
4. FDA vaccine advisors back Moderna’s flu vaccine, bucking past FDA leadership
5. AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates
6. Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues
7. Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win
8. Definium reports Phase 3 hit for LSD drug in severe form of depression
more stories
• 
Lydia Ramsey Pflanzer
.

We here at Endpoints News are celebrating our 10-year anniversary! Readers, thanks for being here along the journey. Cheers to the next decade!
.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
HHS Secretary Robert F. Kennedy Jr. (AP Photo/Jacquelyn Martin)
1
by Max Bayer

The Trump ad­min­is­tra­tion is re­spond­ing to a drum­beat of calls from the biotech and phar­ma in­dus­tries to mod­ern­ize and ex­pe­dite clin­i­cal tri­als with a sweep­ing...

Read the full story
2
by Anna Brown

A WuXi Bi­o­log­ics fac­to­ry un­der con­struc­tion in Mass­a­chu­setts is slat­ed to be com­plet­ed in 2028 — a decade af­ter the com­pa­ny first an­nounced its plans...

Read the full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
3
by Drew Armstrong

I don't know who will win the de­bate on Chi­na biotech in Wash­ing­ton, but I do know which voic­es are the loud­est.

Over the past...

Read the full story
4
by Max Bayer

Every mem­ber of a vac­cine ad­vi­so­ry pan­el for the FDA vot­ed in fa­vor of Mod­er­na’s flu vac­cine, af­ter the prod­uct faced road­blocks from pre­vi­ous agency...

Read the full story
5
by Kyle LaHucik

Ab­b­Vie is mak­ing its largest post-Al­ler­gan ac­qui­si­tion in a $10.9 bil­lion move for im­munol­o­gy biotech Apogee Ther­a­peu­tics.

Apogee's long-act­ing IL-13 drug, called zu­milok­ibart, is slat­ed...